COMUNICADO: Se aprueba la utilización de Herceptin(R) en Europa en combinación con un inhibidor de la aromatasa (y 2)

-- Roche en oncología: www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf

-- Roche Health Kiosk sobre cáncer: www.health-kiosk.ch/start_krebs

-- Video clips, en emisión estándar, libre de cargos: www.thenewsmarket.com

(i) Kaufman, B. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO) Congress, Abstract no. LBA2, 2006.

(ii) Chu KC, Anderson WF. Breast Cancer Res Treat 2002;74:199-211.

(iii) Fornier M, Risio M, Van Poznak C, Seidman A. Oncology 2002;16:1340-1358.

(iv) Penault-Llorca F, Vincent Salomon A, Mathieu MC et al. Ann Oncol 2002;13:(Suppl 5):49 (Abstract 176P)

(v) Arpino G, Green SJ, Allred DC et al. Clinical Cancer Res 2004;10:5670-5676.

(vi) Organización Mundial de la Salud, 2000.

(vii) Extra JM, Cognetti F, Maraninchi D et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Abstract #555, American Society for Clinical Oncology (ASCO) Annual Meeting 2005.

Contacto: Harriet Farmer (Ketchum), Tel: +44-(0)-207-611-3618, Email: harriet.farmer@ketchum.com

WhatsAppFacebookTwitterLinkedinBeloudBluesky